{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:14:01Z","timestamp":1793970841472,"version":"4.8.0"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lunds Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007459","name":"Ragnar S\u00f6derbergs stiftelse","doi-asserted-by":"publisher","award":["M13\/18"],"award-info":[{"award-number":["M13\/18"]}],"id":[{"id":"10.13039\/100007459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2018-02266"],"award-info":[{"award-number":["2018-02266"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jvacx.2024.100452","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T13:00:39Z","timestamp":1706619639000},"page":"100452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Outlining recent updates on influenza therapeutics and vaccines: A comprehensive review"],"prefix":"10.1016","volume":"17","author":[{"given":"Shiza","family":"Malik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Asghar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir","family":"Waheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0005","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/nyas.12462","article-title":"Continuing challenges in influenza","volume":"1323","author":"Webster","year":"2014","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100452_b0010","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/irv.12446","article-title":"Influenza antivirals currently in late-phase clinical trial","volume":"11","author":"Koszalka","year":"2017","journal-title":"Influenza Other Respir Viruses"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100452_b0015","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/cid\/cit725","article-title":"The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts","volume":"58","author":"Memoli","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100452_b0020","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1164\/rccm.201309-1616OC","article-title":"Mucosal immune responses predict clinical outcomes during influenza infection independently of age and viral load","volume":"189","author":"Oshansky","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jvacx.2024.100452_b0025","doi-asserted-by":"crossref","unstructured":"Cole SL et al. M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza. JCI Insight 2017;2(7).","DOI":"10.1172\/jci.insight.91868"},{"key":"10.1016\/j.jvacx.2024.100452_b0030","doi-asserted-by":"crossref","unstructured":"Stramer SL et al. Sensitive detection assays for influenza RNA do not reveal viremia in US blood donors. J Infect Diseases 2012;205(6):886\u2013894.","DOI":"10.1093\/infdis\/jir863"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100452_b0035","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.3201\/eid1211.060426","article-title":"Review of aerosol transmission of influenza A virus","volume":"12","author":"Tellier","year":"2006","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00441-010-1043-z","article-title":"Respiratory epithelial cells in innate immunity to influenza virus infection","volume":"343","author":"Sanders","year":"2011","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.jvacx.2024.100452_b0045","series-title":"Influenza","author":"Kilbourne","year":"2012"},{"issue":"9","key":"10.1016\/j.jvacx.2024.100452_b0050","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1586\/14760584.2013.824709","article-title":"The evolving history of influenza viruses and influenza vaccines","volume":"12","author":"Hannoun","year":"2013","journal-title":"Expert Rev Vac"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100452_b0055","doi-asserted-by":"crossref","first-page":"a038463","DOI":"10.1101\/cshperspect.a038463","article-title":"Influenza therapeutics in clinical practice\u2014challenges and recent advances","volume":"11","author":"Beigel","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100452_b0060","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.coviro.2011.09.002","article-title":"Antivirals and resistance: influenza virus","volume":"1","author":"Ison","year":"2011","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.jvacx.2024.100452_b0065","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fmicb.2020.00135","article-title":"Broadly protective strategies against influenza viruses: universal vaccines and therapeutics","volume":"11","author":"Vogel","year":"2020","journal-title":"Front Microbiol"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100452_b0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/tropicalmed4020067","article-title":"Antiviral therapy for the next influenza pandemic","volume":"4","author":"Hurt","year":"2019","journal-title":"Trop Med Infect Dis"},{"issue":"1775","key":"10.1016\/j.jvacx.2024.100452_b0075","doi-asserted-by":"crossref","first-page":"20180257","DOI":"10.1098\/rstb.2018.0257","article-title":"A brief history of bird flu","volume":"374","author":"Lycett","year":"2019","journal-title":"Philos Trans R Soc B"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100452_b0080","doi-asserted-by":"crossref","first-page":"282","DOI":"10.5958\/2231-5659.2019.00045.6","article-title":"A comprehensive review on: swine flu","volume":"9","author":"Lokhande","year":"2019","journal-title":"Asian J Res Pharmaceut Sci"},{"key":"10.1016\/j.jvacx.2024.100452_b0085","series-title":"in Synthetic Biology","first-page":"141","article-title":"Alignment-Free Analyses of Nucleic Acid Sequences Using Graphical Representation (with Special Reference to Pandemic Bird Flu and Swine Flu)","author":"Nandy","year":"2018"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100452_b0090","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/med.21289","article-title":"Emerging antiviral strategies to interfere with influenza virus entry","volume":"34","author":"Vanderlinden","year":"2014","journal-title":"Med Res Rev"},{"key":"10.1016\/j.jvacx.2024.100452_b0095","unstructured":"Wai HS, Mandalay M, Myint WW, Meiktila M, Win EP. Detection H5N1 Flu for Chicken Using Feature Extraction."},{"key":"10.1016\/j.jvacx.2024.100452_b0100","unstructured":"Duwe S. Influenza viruses\u2013antiviral therapy and resistance. GMS Infect Dis 2017;5."},{"issue":"19","key":"10.1016\/j.jvacx.2024.100452_b0105","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1007\/s00018-014-1615-2","article-title":"Antiviral strategies against influenza virus: towards new therapeutic approaches","volume":"71","author":"Loregian","year":"2014","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0110","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/infdis\/jiq012","article-title":"Emerging influenza antiviral resistance threats","volume":"203","author":"Hayden","year":"2011","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100452_b0115","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2021.02.030","article-title":"Novel approaches for vaccine development","volume":"184","author":"Gebre","year":"2021","journal-title":"Cell"},{"issue":"1\u20132","key":"10.1016\/j.jvacx.2024.100452_b0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.virusres.2011.09.022","article-title":"Immune responses to influenza virus infection","volume":"162","author":"Kreijtz","year":"2011","journal-title":"Virus Res"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrmicro.2017.118","article-title":"The evolution of seasonal influenza viruses","volume":"16","author":"Petrova","year":"2018","journal-title":"Nat Rev Microbiol"},{"issue":"04","key":"10.1016\/j.jvacx.2024.100452_b0130","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1055\/s-0036-1584801","article-title":"Human influenza virus infections","volume":"37","author":"Peteranderl","year":"2016","journal-title":"Semin Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-10-104","article-title":"New treatments for influenza","volume":"10","author":"Barik","year":"2012","journal-title":"BMC Med"},{"key":"10.1016\/j.jvacx.2024.100452_b0140","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/82_2014_395","article-title":"Influenza A virus reassortment","volume":"I","author":"Steel","year":"2014","journal-title":"Influenza Pathogenesis and Control-Volume"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100452_b0145","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/v8040096","article-title":"Current approaches for diagnosis of influenza virus infections in humans","volume":"8","author":"Vemula","year":"2016","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100452_b0150","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/CMR.00097-12","article-title":"Traditional and new influenza vaccines","volume":"26","author":"Wong","year":"2013","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0155","doi-asserted-by":"crossref","first-page":"e2014","DOI":"10.1002\/rmv.2014","article-title":"Influenza vaccine: where are we and where do we go?","volume":"29","author":"Keshavarz","year":"2019","journal-title":"Rev Med Virol"},{"issue":"26","key":"10.1016\/j.jvacx.2024.100452_b0160","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1016\/j.vaccine.2016.03.085","article-title":"Universal influenza vaccines: Shifting to better vaccines","volume":"34","author":"Scorza","year":"2016","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.jvacx.2024.100452_b0165","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.3390\/v7102875","article-title":"Modeling influenza virus infection: a roadmap for influenza research","volume":"7","author":"Boianelli","year":"2015","journal-title":"Viruses"},{"issue":"s2","key":"10.1016\/j.jvacx.2024.100452_b0170","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/irv.12080","article-title":"Routes of influenza transmission","volume":"7","author":"Killingley","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100452_b0175","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/vaccines3020373","article-title":"Influenza vaccination strategies: comparing inactivated and live attenuated influenza vaccines","volume":"3","author":"Sridhar","year":"2015","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0180","first-page":"E28","article-title":"Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden","volume":"57","author":"Tisa","year":"2016","journal-title":"J Prev Med Hyg"},{"issue":"10","key":"10.1016\/j.jvacx.2024.100452_b0185","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1080\/21645515.2015.1091130","article-title":"Evaluating the case for trivalent or quadrivalent influenza vaccines","volume":"12","author":"Baxter","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100452_b0190","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.vaccine.2018.11.076","article-title":"A trivalent gC2\/gD2\/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection","volume":"37","author":"Hook","year":"2019","journal-title":"Vaccine"},{"issue":"45","key":"10.1016\/j.jvacx.2024.100452_b0195","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1016\/j.vaccine.2016.08.057","article-title":"Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications","volume":"34","author":"Sparrow","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2024.100452_b0200","doi-asserted-by":"crossref","unstructured":"HSU AC, See Hv, Hansbro PM, Wark PAB. \u201cInnate immunity to influenza in chronic airways diseases. Respirology 2012;17(8):1166\u20131175.","DOI":"10.1111\/j.1440-1843.2012.02200.x"},{"key":"10.1016\/j.jvacx.2024.100452_b0205","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.indcrop.2016.02.034","article-title":"In vitro evaluation of once a day chronotherapeutic drug delivery system of Gymnema sylvestre","volume":"88","author":"Jain","year":"2016","journal-title":"Ind Crops Prod"},{"key":"10.1016\/j.jvacx.2024.100452_b0210","doi-asserted-by":"crossref","unstructured":"Ahearn CP, Gallo MC, Murphy TF. Insights on persistent airway infection by non-typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Pathog Dis 2017;75(4).","DOI":"10.1093\/femspd\/ftx042"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100452_b0215","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2165\/11537960-000000000-00000","article-title":"Drugs in development for influenza","volume":"70","author":"Boltz","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.jvacx.2024.100452_b0220","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fimmu.2016.00317","article-title":"Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy","volume":"7","author":"S\u00e1nchez-Ram\u00f3n","year":"2016","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100452_b0225","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3349\/ymj.2013.54.3.560","article-title":"Tools to detect influenza virus","volume":"54","author":"Kim","year":"2013","journal-title":"Yonsei Med J"},{"issue":"12","key":"10.1016\/j.jvacx.2024.100452_b0230","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S1473-3099(14)70821-7","article-title":"Antiviral combinations for severe influenza","volume":"14","author":"Dunning","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100452_b0235","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.2105\/AJPH.2012.301137","article-title":"The burden of influenza B: a structured literature review","volume":"103","author":"Paul Glezen","year":"2013","journal-title":"Am J Public Health"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0240","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrmicro3367","article-title":"At the centre: influenza A virus ribonucleoproteins","volume":"13","author":"Eisfeld","year":"2015","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100452_b0245","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1039\/C4MD00143E","article-title":"Multivalent glycoconjugates as vaccines and potential drug candidates","volume":"5","author":"Bhatia","year":"2014","journal-title":"Medchemcomm"},{"key":"10.1016\/j.jvacx.2024.100452_b0250","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.trsl.2020.01.005","article-title":"Next-generation direct-acting influenza therapeutics","volume":"220","author":"Toots","year":"2020","journal-title":"Transl Res"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-10-321","article-title":"Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase","volume":"10","author":"Cohen","year":"2013","journal-title":"Virol J"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100452_b0260","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/0091270012440280","article-title":"Pharmacokinetic Properties ofAnti-Influenza Neuraminidase Inhibitors","volume":"53","author":"Chairat","year":"2013","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100452_b0265","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.antiviral.2013.03.014","article-title":"Influenza virus resistance to neuraminidase inhibitors","volume":"98","author":"Samson","year":"2013","journal-title":"Antiviral Res"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100452_b0270","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.antiviral.2013.08.023","article-title":"Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance","volume":"100","author":"Burnham","year":"2013","journal-title":"Antiviral Res"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100452_b0275","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/cid\/ciw255","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate as post-exposure prophylaxis for influenza","volume":"63","author":"Kashiwagi","year":"2016","journal-title":"Rev Infect Dis"},{"issue":"10","key":"10.1016\/j.jvacx.2024.100452_b0280","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/eri.11.112","article-title":"Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza","volume":"9","author":"Ikematsu","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jvacx.2024.100452_b0285","series-title":"Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors","author":"Fage","year":"2017"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100452_b0290","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1128\/AAC.01755-09","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection","volume":"54","author":"Sugaya","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100452_b0295","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3851\/IMP1688","article-title":"Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza","volume":"21","author":"Yamashita","year":"2010","journal-title":"Antivir Chem Chemother"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100452_b0300","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","article-title":"Influenza virus polymerase inhibitors in clinical development","volume":"32","author":"Hayden","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jvacx.2024.100452_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104545","article-title":"Antivirals targeting the polymerase complex of influenza viruses","volume":"169","author":"Mifsud","year":"2019","journal-title":"Antiviral Res"},{"issue":"16","key":"10.1016\/j.jvacx.2024.100452_b0310","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1073\/pnas.1119817109","article-title":"Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase","volume":"109","author":"Muratore","year":"2012","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0315","first-page":"1","article-title":"A novel small-molecule inhibitor of influenza A virus acts by suppressing PA endonuclease activity of the viral polymerase","volume":"6","author":"Yuan","year":"2016","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.jvacx.2024.100452_b0320","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1021\/acs.jmedchem.6b01227","article-title":"Inhibitors of influenza virus polymerase acidic (PA) endonuclease: contemporary developments and perspectives","volume":"60","author":"Ju","year":"2017","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100452_b0325","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/med.21401","article-title":"The influenza virus polymerase complex: an update on its structure, functions, and significance for antiviral drug design","volume":"36","author":"Stevaert","year":"2016","journal-title":"Med Res Rev"},{"key":"10.1016\/j.jvacx.2024.100452_b0330","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antiviral Res"},{"issue":"24","key":"10.1016\/j.jvacx.2024.100452_b0335","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1002\/smll.201001349","article-title":"Inhibition of influenza virus infection by multivalent sialic-acid-functionalized gold nanoparticles","volume":"6","author":"Papp","year":"2010","journal-title":"Small"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100452_b0340","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1073\/pnas.1617020114","article-title":"Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol","volume":"114","author":"Kadam","year":"2017","journal-title":"Proc Natl Acad Sci"},{"issue":"6362","key":"10.1016\/j.jvacx.2024.100452_b0345","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1126\/science.aan0516","article-title":"Potent peptidic fusion inhibitors of influenza virus","volume":"358","author":"Kadam","year":"1979","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100452_b0350","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1021\/jm1002183","article-title":"Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy","volume":"53","author":"Matsubara","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.jvacx.2024.100452_b0355","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1155\/2018\/9747549","article-title":"Evolution of therapeutic antibodies, influenza virus biology, influenza, and influenza immunotherapy","volume":"2018","author":"Chaisri","year":"2018","journal-title":"Biomed Res Int"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0360","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/cmi.2015.74","article-title":"The cytokine storm of severe influenza and development of immunomodulatory therapy","volume":"13","author":"Liu","year":"2016","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100452_b0365","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/irv.12706","article-title":"Meeting report and review: Immunological assays and correlates of protection for next-generation influenza vaccines","volume":"14","author":"Krammer","year":"2020","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.jvacx.2024.100452_b0370","first-page":"1","article-title":"Broadly neutralizing antibodies for therapy of viral infections","volume":"6","author":"Srinivasan","year":"2016","journal-title":"Antibody Technol J"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100452_b0375","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cmi.2017.02.009","article-title":"Universal influenza virus vaccines and therapeutic antibodies","volume":"23","author":"Nachbagauer","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"30","key":"10.1016\/j.jvacx.2024.100452_b0380","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1016\/j.vaccine.2015.05.049","article-title":"Competitive detection of influenza neutralizing antibodies using a novel bivalent fluorescence-based microneutralization assay (BiFMA)","volume":"33","author":"Baker","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100452_b0385","doi-asserted-by":"crossref","first-page":"e00430","DOI":"10.1128\/mBio.00430-18","article-title":"Identification of the I38T PA substitution as a resistance marker for next-generation influenza virus endonuclease inhibitors","volume":"9","author":"Jones","year":"2018","journal-title":"MBio"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100452_b0390","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00775-015-1292-0","article-title":"Investigation of the salicylaldehyde thiosemicarbazone scaffold for inhibition of influenza virus PA endonuclease","volume":"20","author":"Rogolino","year":"2015","journal-title":"J Biol Inorg Chem"},{"key":"10.1016\/j.jvacx.2024.100452_b0395","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fcimb.2019.00067","article-title":"Virtual screen for repurposing of drugs for candidate influenza a M2 ion-channel inhibitors","volume":"9","author":"Radosevic","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100452_b0400","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ni.1861","article-title":"Influenza virus activates inflammasomes via its intracellular M2 ion channel","volume":"11","author":"Ichinohe","year":"2010","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100452_b0405","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41573-019-0056-x","article-title":"Next-generation influenza vaccines: opportunities and challenges","volume":"19","author":"Wei","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jvacx.2024.100452_b0410","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/B978-0-12-405880-4.00006-8","article-title":"Influenza virus resistance to antiviral therapy","volume":"67","author":"van der Vries","year":"2013","journal-title":"Adv Pharmacol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0415","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/cells9010137","article-title":"RNA-based therapeutics: from antisense oligonucleotides to miRNAs","volume":"9","author":"Bajan","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100452_b0420","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/vaccines6020020","article-title":"New kids on the block: RNA-based influenza virus vaccines","volume":"6","author":"Scorza","year":"2018","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jvacx.2024.100452_b0425","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/978-3-031-08415-7_16","article-title":"\u201cDelivery vehicles for self-amplifying RNA","author":"Bathula","year":"2022","journal-title":"Messenger RNA Therapeutics Springer"},{"issue":"21","key":"10.1016\/j.jvacx.2024.100452_b0430","doi-asserted-by":"crossref","first-page":"12884","DOI":"10.3390\/ijms232112884","article-title":"Self-Amplifying RNA Approach for Protein Replacement Therapy","volume":"23","author":"Papukashvili","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0435","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJMp1714916","article-title":"Chasing seasonal influenza\u2014the need for a universal influenza vaccine","volume":"378","author":"Paules","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100452_b0440","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/jac\/dkq100","article-title":"Targeting pandemic influenza: a primer on influenza antivirals and drug resistance","volume":"65","author":"Moss","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100452_b0445","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/irv.12470","article-title":"The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection","volume":"11","author":"Sellers","year":"2017","journal-title":"Influenza Other Respir Viruses"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0450","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-065X.2010.00974.x","article-title":"Influenza vaccine immunology","volume":"239","author":"Dormitzer","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jvacx.2024.100452_b0455","first-page":"2015","article-title":"Prospects of HA-based universal influenza vaccine","author":"Hashem","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jvacx.2024.100452_b0460","doi-asserted-by":"crossref","unstructured":"M\u00fcller KH, Kakkola L, Nagaraj AS, Cheltsov Av, Anastasina M, Kainov DE. Emerging cellular targets for influenza antiviral agents. Trends Pharmacol Sci 2012;33(2):89\u201399.","DOI":"10.1016\/j.tips.2011.10.004"},{"issue":"21","key":"10.1016\/j.jvacx.2024.100452_b0465","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMra1002842","article-title":"Influenza vaccines for the future","volume":"363","author":"Lambert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvacx.2024.100452_b0470","doi-asserted-by":"crossref","unstructured":"Clar C, Oseni Z, Flowers N, Keshtkar\u2010Jahromi M, Rees K. Influenza vaccines for preventing cardiovascular disease. Cochrane Database of Systematic Reviews, no. 5, 2015.","DOI":"10.1002\/14651858.CD005050.pub3"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100452_b0475","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1056\/NEJMoa1700153","article-title":"Influenza vaccine effectiveness in the United States during the 2015\u20132016 season","volume":"377","author":"Jackson","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100452_b0480","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1378\/chest.12-1711","article-title":"Immunobiology of influenza vaccines","volume":"143","author":"Lorenzo","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jvacx.2024.100452_b0485","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1093\/infdis\/jiz017","article-title":"Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection","volume":"219","author":"Eichelberger","year":"2019","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.jvacx.2024.100452_b0490","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00705-016-2907-7","article-title":"Influenza virus neuraminidase (NA): a target for antivirals and vaccines","volume":"161","author":"Jagadesh","year":"2016","journal-title":"Arch Virol"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100452_b0495","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3390\/vaccines9070739","article-title":"M2e-based influenza vaccines with nucleoprotein a review","volume":"9","author":"Tan","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"32","key":"10.1016\/j.jvacx.2024.100452_b0500","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1016\/j.vaccine.2011.05.041","article-title":"Safety and immunogenicity of a recombinant M2e\u2013flagellin influenza vaccine (STF2. 4xM2e) in healthy adults","volume":"29","author":"Turley","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.jvacx.2024.100452_b0505","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1038\/mt.2010.202","article-title":"A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge","volume":"18","author":"Zhou","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jvacx.2024.100452_b0510","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1093\/infdis\/jiz003","article-title":"The role of matrix protein 2 ectodomain in the development of universal influenza vaccines","volume":"219","author":"Saelens","year":"2019","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100452_b0515","doi-asserted-by":"crossref","first-page":"e9812","DOI":"10.1371\/journal.pone.0009812","article-title":"Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret","volume":"5","author":"Rao","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jvacx.2024.100452_b0520","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3389\/fbioe.2015.00197","article-title":"Production of H5N1 influenza virus matrix protein 2 ectodomain protein bodies in tobacco plants and in insect cells as a candidate universal influenza vaccine","volume":"3","author":"Mbewana","year":"2015","journal-title":"Front Bioeng Biotechnol"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100452_b0525","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4161\/21645515.2014.995056","article-title":"Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48\/80 adjuvant","volume":"11","author":"Zheng","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100452_b0530","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.00615-10","article-title":"Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management","volume":"55","author":"Piret","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"17","key":"10.1016\/j.jvacx.2024.100452_b0535","doi-asserted-by":"crossref","first-page":"8450","DOI":"10.1021\/acs.analchem.6b00502","article-title":"Bioassay development for ultrasensitive detection of influenza a nucleoprotein using digital ELISA","volume":"88","author":"Leirs","year":"2016","journal-title":"Anal Chem"},{"key":"10.1016\/j.jvacx.2024.100452_b0540","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.coviro.2017.04.005","article-title":"Inactivated influenza virus vaccines: the future of TIV and QIV","volume":"23","author":"Schotsaert","year":"2017","journal-title":"Curr Opin Virol"},{"issue":"9","key":"10.1016\/j.jvacx.2024.100452_b0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.crmeth.2022.100287","article-title":"A chemical method for generating live-attenuated, replication-defective DNA viruses for vaccine development","volume":"2","author":"Jaijyan","year":"2022","journal-title":"Cell Reports Methods"},{"issue":"12","key":"10.1016\/j.jvacx.2024.100452_b0550","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2165\/11206860-000000000-00000","article-title":"Live attenuated influenza vaccine (FluMist\u00ae; FluenzTM)","volume":"71","author":"Carter","year":"2011","journal-title":"Drugs"},{"issue":"44","key":"10.1016\/j.jvacx.2024.100452_b0555","doi-asserted-by":"crossref","first-page":"7849","DOI":"10.1016\/j.vaccine.2011.07.093","article-title":"Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses","volume":"29","author":"Lanthier","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0560","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4161\/hv.8.1.17623","article-title":"The rationale for quadrivalent influenza vaccines","volume":"8","author":"Ambrose","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"14","key":"10.1016\/j.jvacx.2024.100452_b0565","doi-asserted-by":"crossref","first-page":"7793","DOI":"10.1128\/JVI.00979-13","article-title":"Recombinant IgA is sufficient to prevent influenza virus transmission in guinea pigs","volume":"87","author":"Seibert","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2024.100452_b0570","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.virol.2020.08.003","article-title":"Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope","volume":"550","author":"Kim","year":"2020","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100452_b0575","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12250-012-3241-1","article-title":"Developments of subunit and VLP vaccines against influenza A virus","volume":"27","author":"Deng","year":"2012","journal-title":"Virol Sin"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100452_b0580","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/biologics2040018","article-title":"Virus-like Particles (VLPs) as Important Tools for Flavivirus Vaccine Development","volume":"2","author":"Castilho","year":"2022","journal-title":"Biologics"},{"issue":"15","key":"10.1016\/j.jvacx.2024.100452_b0585","doi-asserted-by":"crossref","first-page":"7760","DOI":"10.1128\/JVI.01849-09","article-title":"Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization","volume":"84","author":"Quan","year":"2010","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100452_b0590","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4161\/hv.18757","article-title":"Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic","volume":"8","author":"L\u00f3pez-Mac\u00edas","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jvacx.2024.100452_b0595","doi-asserted-by":"crossref","unstructured":"Grant EJ, Chen L, Quinones-Parra S, Pang K, Kedzierska K, Chen W. T-cell immunity to influenza A viruses. Crit Rev Immunol 2014;34(1).","DOI":"10.1615\/CritRevImmunol.2013010019"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0600","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/icb.2012.54","article-title":"The design and proof of concept for a CD8+ T cell-based vaccine inducing cross-subtype protection against influenza A virus","volume":"91","author":"Tan","year":"2013","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0605","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/cid\/cis327","article-title":"Preliminary assessment of the efficacy of a t-cell\u2013based influenza vaccine, MVA-NP+ M1, in humans","volume":"55","author":"Lillie","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jvacx.2024.100452_b0610","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3389\/fimmu.2018.01568","article-title":"A review of DNA vaccines against influenza","volume":"9","author":"Lee","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0615","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1600-065X.2010.00980.x","article-title":"DNA vaccines: an historical perspective and view to the future","volume":"239","author":"Liu","year":"2011","journal-title":"Immunol Rev"},{"issue":"47","key":"10.1016\/j.jvacx.2024.100452_b0620","doi-asserted-by":"crossref","first-page":"8549","DOI":"10.1016\/j.vaccine.2011.09.029","article-title":"Preparation and immunological effectiveness of a swine influenza DNA vaccine encapsulated in chitosan nanoparticles","volume":"29","author":"Zhao","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-019-0114-8","article-title":"Heterologous prime-boost with A (H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost","volume":"4","author":"Levine","year":"2019","journal-title":"NPJ Vaccines"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100452_b0630","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.vaccine.2009.10.105","article-title":"Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model","volume":"28","author":"Sabarth","year":"2010","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13567-020-00810-z","article-title":"Exploring heterologous prime-boost vaccination approaches to enhance influenza control in pigs","volume":"51","author":"Li","year":"2020","journal-title":"Vet Res"},{"issue":"12","key":"10.1016\/j.jvacx.2024.100452_b0640","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.3390\/vaccines9121465","article-title":"Cross-reactivity conferred by homologous and heterologous prime-boost A\/H5 influenza vaccination strategies in humans: a literature review","volume":"9","author":"Kok","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100452_b0645","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/infdis\/jit180","article-title":"Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect","volume":"208","author":"Ledgerwood","year":"2013","journal-title":"J Infect Dis"},{"issue":"42","key":"10.1016\/j.jvacx.2024.100452_b0650","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.1016\/j.vaccine.2017.08.059","article-title":"Short-and long-term protective efficacy against clade 2.3. 4.4 H5N2 highly pathogenic avian influenza virus following prime-boost vaccination in turkeys","volume":"35","author":"Santos","year":"2017","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100452_b0655","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4110\/in.2015.15.2.51","article-title":"Recent advances of vaccine adjuvants for infectious diseases","volume":"15","author":"Lee","year":"2015","journal-title":"Immune Netw"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100452_b0660","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1586\/14760584.2013.811195","article-title":"Influenza virosomes as vaccine adjuvant and carrier system","volume":"12","author":"Moser","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100452_b0665","doi-asserted-by":"crossref","first-page":"e88979","DOI":"10.1371\/journal.pone.0088979","article-title":"GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza","volume":"9","author":"Clegg","year":"2014","journal-title":"PLoS One"},{"issue":"52","key":"10.1016\/j.jvacx.2024.100452_b0670","doi-asserted-by":"crossref","first-page":"7658","DOI":"10.1016\/j.vaccine.2012.10.007","article-title":"Adjuvants in influenza vaccines","volume":"30","author":"Tetsutani","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100452_b0675","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.antiviral.2010.08.016","article-title":"Inhibition of influenza virus replication by plant-derived isoquercetin","volume":"88","author":"Kim","year":"2010","journal-title":"Antiviral Res"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100452_b0680","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1002\/jmv.26163","article-title":"The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak","volume":"92","author":"Yue","year":"2020","journal-title":"J Med Virol"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100452_b0685","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00038-020-01463-7","article-title":"The psychosocial impact of flu influenza pandemics on healthcare workers and lessons learnt for the COVID-19 emergency: a rapid review","volume":"65","author":"Barello","year":"2020","journal-title":"Int J Public Health"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100452_b0690","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.chom.2015.02.012","article-title":"Influenza vaccines: challenges and solutions","volume":"17","author":"Houser","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jvacx.2024.100452_b0695","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejpb.2015.05.023","article-title":"Current and next generation influenza vaccines: Formulation and production strategies","volume":"94","author":"Soema","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0700","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(11)70295-X","article-title":"Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis","volume":"12","author":"Osterholm","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0705","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nnano.2016.181","article-title":"Nanostructured glycan architecture is important in the inhibition of influenza A virus infection","volume":"12","author":"Kwon","year":"2017","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.jvacx.2024.100452_b0710","first-page":"2015","article-title":"Antiviral potential of algae polysaccharides isolated from marine sources: a review","author":"Ahmadi","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jvacx.2024.100452_b0715","doi-asserted-by":"crossref","unstructured":"Credille Cv, Chen Y, Cohen SM. Fragment-based identification of influenza endonuclease inhibitors. J Med Chem 59(13) (2016) 6444\u20136454.","DOI":"10.1021\/acs.jmedchem.6b00628"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100452_b0720","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/thoraxjnl-2011-200160","article-title":"Combined Haemophilus influenzae respiratory infection and allergic airways disease drives chronic infection and features of neutrophilic asthma","volume":"67","author":"Essilfie","year":"2012","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100452_b0725","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1128\/JVI.01433-09","article-title":"Hemagglutinin-pseudotyped green fluorescent protein-expressing influenza viruses for the detection of influenza virus neutralizing antibodies","volume":"84","author":"Mart\u00ednez-Sobrido","year":"2010","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100452_b0730","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.antiviral.2012.09.020","article-title":"Prophylactic, therapeutic and neutralizing effects of zinc oxide tetrapod structures against herpes simplex virus type-2 infection","volume":"96","author":"Antoine","year":"2012","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0735","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-22958-8","article-title":"Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival","volume":"12","author":"Dispinseri","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jvacx.2024.100452_b0740","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3389\/fvets.2019.00482","article-title":"Hemagglutinin-specific non-neutralizing antibody is essential for protection provided by inactivated and viral-vectored H7N9 avian influenza vaccines in chickens","volume":"6","author":"Hu","year":"2020","journal-title":"Front Vet Sci"},{"issue":"9","key":"10.1016\/j.jvacx.2024.100452_b0745","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3390\/v13091779","article-title":"Universally immune: how infection permissive next generation influenza vaccines may affect population immunity and viral spread","volume":"13","author":"Bull","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jvacx.2024.100452_b0750","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac168","article-title":"Global epidemiology of human infections with variant influenza viruses, 1959\u20132021: A descriptive study","author":"Chen","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.jvacx.2024.100452_b0755","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3390\/v20801530","article-title":"Animal models for influenza virus pathogenesis and transmission","volume":"2","author":"Bouvier","year":"2010","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0760","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-019-2491-9","article-title":"Influenza virus-related critical illness: prevention, diagnosis, treatment","volume":"23","author":"Chow","year":"2019","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100452_b0765","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jiph.2015.10.009","article-title":"The environmental deposition of influenza virus from patients infected with influenza A (H1N1) pdm09: Implications for infection prevention and control","volume":"9","author":"Killingley","year":"2016","journal-title":"J Infect Public Health"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100452_b0770","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.chom.2018.04.003","article-title":"An immunocompetent mouse model of Zika virus infection","volume":"23","author":"Gorman","year":"2018","journal-title":"Cell Host Microbe"},{"issue":"8","key":"10.1016\/j.jvacx.2024.100452_b0775","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nrmicro2613","article-title":"Influenza A viruses: new research developments","volume":"9","author":"Medina","year":"2011","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100452_b0780","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/rmv.1713","article-title":"Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines","volume":"22","author":"Marcelin","year":"2012","journal-title":"Rev Med Virol"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100452_b0785","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02180-19","article-title":"Generation of DelNS1 influenza viruses: a strategy for optimizing live attenuated influenza vaccines","volume":"10","author":"Wang","year":"2019","journal-title":"MBio"},{"issue":"8","key":"10.1016\/j.jvacx.2024.100452_b0790","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1128\/JVI.07203-11","article-title":"Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread","volume":"86","author":"Awasthi","year":"2012","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0795","doi-asserted-by":"crossref","first-page":"26","DOI":"10.11599\/germs.2013.1034","article-title":"DNA vaccines: roles against diseases","volume":"3","author":"Khan","year":"2013","journal-title":"Germs"},{"issue":"13","key":"10.1016\/j.jvacx.2024.100452_b0800","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.vaccine.2010.01.029","article-title":"Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin","volume":"28","author":"Smith","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100452_b0805","doi-asserted-by":"crossref","first-page":"e94051","DOI":"10.1371\/journal.pone.0094051","article-title":"Mucosal vaccination with recombinant Lactobacillus casei-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB\/c mice","volume":"9","author":"Chowdhury","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0810","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12896-015-0164-6","article-title":"Rapid high-yield expression of a candidate influenza vaccine based on the ectodomain of M2 protein linked to flagellin in plants using viral vectors","volume":"15","author":"Mardanova","year":"2015","journal-title":"BMC Biotechnol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100452_b0815","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.virol.2012.04.015","article-title":"In contrast to conventional inactivated influenza vaccines, 4xM2e. HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran","volume":"430","author":"Ebrahimi","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.jvacx.2024.100452_b0820","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1590\/1807-57622017.0425","article-title":"Therapeutic paths, care and assistance in the construction of ideas about maternity and childhood in the context of the Zika virus","volume":"22","author":"Scott","year":"2018","journal-title":"Interface-Comunica\u00e7\u00e3o, Sa\u00fade, Educa\u00e7\u00e3o"},{"issue":"22","key":"10.1016\/j.jvacx.2024.100452_b0825","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvacx.2024.100452_b0830","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/471468","article-title":"Cholesteryl pullulan encapsulated TNF-\u03b1 nanoparticles are an effective mucosal vaccine adjuvant against influenza virus","volume":"2015","author":"Nagatomo","year":"2015","journal-title":"Biomed Res Int"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224000251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224000251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:11:01Z","timestamp":1762913461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136224000251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":166,"alternative-id":["S2590136224000251"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100452","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outlining recent updates on influenza therapeutics and vaccines: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100452"}}